SCHEMBL23055245

SCHEMBL23055245

CC(C)Nc1ccc2nsnc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.59
MAPT P10636 8/20 0.54
ALDH1A1 P00352 8/20 0.54
MEN1 O00255 7/20 0.54
KMT2A Q03164 7/20 0.54
BLM P54132 5/20 0.54
GAA P10253 4/20 0.54
APAF1 O14727 2/20 0.54
TDP2 O95551 2/20 0.54
POLB P06746 2/20 0.54
CASP3 P42574 2/20 0.54
SENP8 Q96LD8 2/20 0.54
SENP7 Q9BQF6 2/20 0.54
SENP6 Q9GZR1 2/20 0.54
CASP6 P55212 1/20 0.54
ATM Q13315 1/20 0.54
PTPN11 Q06124 4/20 0.47
PTPN1 P18031 2/20 0.47
THRB P10828 2/20 0.46
RECQL P46063 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13945662 0.78 KDM4E (0.59) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL10094133 0.74 KDM4E (0.53) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL16368599 0.73 KDM4E (0.54) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL19966690 0.73 PTPN11 (0.60) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL8361382 0.70 KDM4E (0.50) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL12890485 0.69 NPC1 (0.50) MAPTALDH1A1POLBRAB9ANSD2
SCHEMBL12890444 0.69 IRAK4 (0.53)
SCHEMBL23432576 0.69 ALDH1A1 (0.47) ALDH1A1NPSR1SMN1; SMN2
SCHEMBL39430 0.68 TDP1 (0.72) MAPTALDH1A1KMT2ABLMGAA
SCHEMBL19966728 0.68 KDM4E (0.49) KDM4EMAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2023-04-13 US disclosed
EP-4104861-A1 THERAPEUTIC AGENT FOR TAUOPATHIES Sumitomo Pharma Co., Ltd. (JP) 2022-12-21 EP disclosed
WO-2021149767-A1 HETEROCYCLIC DERIVATIVE 大日本住友製薬株式会社 2021-07-29 WO disclosed
EP-3828174-A1 PYRIDAZINONE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2021-06-02 EP disclosed
WO-2021039961-A1 RING-FUSED PYRAZOLE DERIVATIVE 大日本住友製薬株式会社 2021-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230109839-A1 THERAPEUTIC AGENT FOR TAUOPATHIES MAPT, PSEN1, PSEN2 KDM4E 3621/4885MAPT 1/4885ALDH1A1 4081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.